Stock Analysis

Infragreen Group (ASX:IFN) delivered a record FY26 result on 26 August 2026, highlighting strong earnings growth across its portfolio of recycling, resource recovery and clean-energy businesses.

EBR Systems (ASX:EBR) continues advancing the commercial rollout of its WiSE CRT System, with implant volumes, hospital adoption and reimbursement progress becoming central themes for the medical technology company.

Temple & Webster Group (ASX:TPW) delivered its FY26 results on 19 August 2026, highlighting continued expansion in its online furniture and homewares platform while also revealing a softer start to FY27 trading.

Botanix Pharmaceuticals (ASX:BOT) continues advancing the commercial rollout of Sofdra while strengthening its intellectual property position around the dermatology treatment.

Trajan Group Holdings (ASX:TRJ) delivered its FY26 full-year results on 27 August 2026, highlighting a significant improvement in second-half operating performance as cost initiatives and operational changes began supporting earnings recovery.

Immutep (ASX:IMM) continues developing its LAG-3 focused biotechnology platform, with recent clinical updates highlighting both encouraging scientific signals and the challenges of advancing experimental therapies.

ImpediMed (ASX:IPD) has expanded the potential application of its SOZO platform after receiving US Food and Drug Administration 510(k) clearance for sarcopenia risk assessment.